Alix Sournia-Saquet

Dr. Alix Sournia-Saquet

CNRS- LCC, Toulouse, Occitanie, France
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JPJulien Pedron
Julien Pedron
CBClotilde Boudot
Clotilde Boudot
SHSébastien Hutter
Sébastien Hutter
SBSandra Bourgeade-Delmas
Sandra Bourgeade-Delmas
JSJean-Luc Stigliani
Jean-Luc Stigliani
PVPierre Verhaeghe
Pierre Verhaeghe
To study the antiparasitic 8-nitroquinolin-2(1H)-one pharmacophore, a series of 31 derivatives was synthesized in 1-5 steps and evaluated in vitro against both Leishmania infantum and Trypanosoma brucei brucei. In parallel, the reduction potential of all molecules was measured by cyclic voltammetry. Structure-activity relationships first indicated that antileishmanial activity depends on an intramolecular hydrogen bond (described by X-ray diffraction) between the lactam function and the nitro group, which is responsible for an important shift of the redox potential (+0.3 V in comparison with 8-nitroquinoline). With the assistance of computational chemistry, a set of derivatives presenting a large range of redox potentials (from -1.1 to -0.45 V) was designed and provided a list of suitable molecules to be synthesized and tested. This approach highlighted that, in this series, only substrates with a redox potential above -0.6 V display activity toward L. infantum. Nevertheless, such relation between redox potentials and in vitro antiparasitic activities was not observed in T. b. brucei. Compound 22 is a new hit compound in the series, displaying both antileishmanial and antitrypanosomal activity along with a low cytotoxicity on the human HepG2 cell line. Compound 22 is selectively bioactivated by the type 1 nitroreductases (NTR1) of L. donovani and T. brucei brucei. Moreover, despite being mutagenic in the Ames test, as most of nitroaromatic derivatives, compound 22 was not genotoxic in the comet assay. Preliminary in vitro pharmacokinetic parameters were finally determined and pointed out a good in vitro microsomal stability (half-life > 40 min) and a 92% binding to human albumin.


23 April 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
CZChongwei Zhu
Chongwei Zhu
Poater AlbertPoater Albert
Poater Albert
CDCarine Duhayon
Carine Duhayon
BKBrice Kauffmann
Brice Kauffmann
ASAlix Sournia-Saquet
Alix Sournia-Saquet
RCRemi Chauvin
Remi Chauvin

13 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Romain Paoli-LombardoRomain Paoli-Lombardo
Romain Paoli-Lombardo
Nicolas PrimasNicolas Primas
Nicolas Primas
SBSandra Bourgeade-Delmas
Sandra Bourgeade-Delmas
SHSébastien Hutter
Sébastien Hutter
ASAlix Sournia-Saquet
Alix Sournia-Saquet
Vanelle PatriceVanelle Patrice
Vanelle Patrice
An antileishmanial structure–activity relationship (SAR) study focused on positions 2 and 8 of the imidazo[1,2-a]pyridine ring was conducted through the synthesis of 22 new derivatives. After being screened on the promatigote and axenic amastigote stages of Leishmania donovani and L. infantum, the best compounds were tested against the intracellular amastigote stage of L. infantum and evaluated regarding their in vitro physicochemical and pharmacokinetic properties, leading to the discovery of a new antileishmanial6-chloro-3-nitro-8-(pyridin-4-yl)-2-[(3,3,3-trifluoropropylsulfonyl)methyl]imidazo[1,2-a]pyridine hit. It displayed low cytotoxicities on both HepG2 and THP1 cell lines (CC50 > 100 µM) associated with a good activity against the intracellular amastigote stage of L. infantum (EC50 = 3.7 µM versus 0.4 and 15.9 µM for miltefosine and fexinidazole, used as antileishmanial drug references). Moreover, in comparison with previously reported derivatives in the studied series, this compound displayed greatly improved aqueous solubility, good mouse microsomal stability (T1/2 > 40 min) and high gastrointestinal permeability in a PAMPA model, making it an ideal candidate for further in vivo studies on an infectious mouse model.

11 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MRMirko Ruamps
Mirko Ruamps
SBStephanie Bastin
Stephanie Bastin
LRLionel Rechignat
Lionel Rechignat
ASAlix Sournia-Saquet
Alix Sournia-Saquet
LVLaure Vendier
Laure Vendier
VCVincent César
Vincent César
The coordination chemistry of the N-heterocyclic carbene ligand IMes(NMe2)2, derived from the well-known IMes ligand by substitution of the carbenic heterocycle with two dimethylamino groups, was investigated with d6 [Mn(I), Fe(II)], d8 [Rh(I)], and d10 [Cu(I)] transition-metal centers. The redox behavior of the resulting organometallic complexes was studied through a combined experimental/theoretical study, involving electrochemistry, EPR spectroscopy, and DFT calculations. While the complexes [CuCl(IMes(NMe2)2)], [RhCl(COD)(IMes(NMe2)2)], and [FeCp(CO)2 (IMes(NMe2)2)](BF4) exhibit two oxidation waves, the first oxidation wave is fully reversible but only for the first complex the second oxidation wave is reversible. The mono-oxidation event for these complexes occurs on the NHC ligand, with a spin density mainly located on the diaminoethylene NHC-backbone, and has a dramatic effect on the donating properties of the NHC ligand. Conversely, as the Mn(I) center in the complex [MnCp(CO)2 ((IMes(NMe2)2)] is easily oxidizable, the latter complex is first oxidized on the metal center to form the corresponding cationic Mn(II) complex, and the NHC ligand is oxidized in a second reversible oxidation wave.

21 January 2015 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
KCKévin Cocq
Kévin Cocq
Valérie MaravalValérie Maraval
Valérie Maraval
NSNathalie Saffon-Merceron
Nathalie Saffon-Merceron
ASAlix Sournia-Saquet
Alix Sournia-Saquet
CPCorentin Poidevin
Corentin Poidevin
RCRemi Chauvin
Remi Chauvin